The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS

Eur Heart J. 2008 Jul;29(14):1709-10. doi: 10.1093/eurheartj/ehn255. Epub 2008 Jun 13.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Anti-Obesity Agents / adverse effects
  • Anti-Obesity Agents / therapeutic use*
  • Cannabinoid Receptor Antagonists*
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / prevention & control*
  • Humans
  • Obesity / complications
  • Obesity / drug therapy
  • Piperidines / adverse effects
  • Piperidines / therapeutic use*
  • Pyrazoles / adverse effects
  • Pyrazoles / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Rimonabant

Substances

  • Anti-Obesity Agents
  • Cannabinoid Receptor Antagonists
  • Piperidines
  • Pyrazoles
  • Rimonabant